The tweet was deleted by the author.
But we saved everything 🙂.
Compass Therapeutics has announced the appointment of Sapna Mehtani as vice president and head of intellectual property.
The addition brings new leadership to the company’s strategy in managing its intellectual property portfolio.
View post on X Loading...
Compass Therapeutics recently presented results from its Phase 2 3 COMPANION 002 trial in advanced biliary tract cancer at ESMO 2026. The study focused on patients with advanced disease. The company continues to advance its pipeline alongside new management appointments.